HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+ tumours are poorly characterised. Our aim was to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergamino, Milana A., López-Knowles, Elena, Morani, Gabriele, Tovey, Holly, Kilburn, Lucy, Schuster, Eugene F., Alataki, Anastasia, Hills, Margaret, Xiao, Hui, Holcombe, Chris, Skene, Anthony, Robertson, John F., Smith, Ian E., Bliss, Judith M., Dowsett, Mitch, Cheang, Maggie C.U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482930/
https://www.ncbi.nlm.nih.gov/pubmed/35985932
http://dx.doi.org/10.1016/j.ebiom.2022.104205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482930/
https://www.ncbi.nlm.nih.gov/pubmed/35985932
http://dx.doi.org/10.1016/j.ebiom.2022.104205

Ejemplares similares